Literature DB >> 8330316

Immunomodulation by an inhibitor of S-adenosyl-L-homocysteine hydrolase: inhibition of in vitro and in vivo allogeneic responses.

J A Wolos1, K A Frondorf, G F Babcock, S A Stripp, T L Bowlin.   

Abstract

The response of murine T cells to MHC class II determinants on allogeneic cells induces helper T cell activation and the development of cytotoxic T cells. We have recently established that an S-adenosyl-L-homocysteine hydrolase inhibitor, (Z)-5'-fluoro-4',5'-didehydro-5'-deoxyadenosine (MDL 28,842), is a potent immunosuppressive agent which selectively inhibits T cell activation. In this report we characterize the effect of MDL 28,842 on in vitro and in vivo models of transplant rejection. In vitro, MDL 28,842 inhibited the generation of cytotoxic T cells in the murine mixed lymphocyte reaction with an IC50 of less than 0.1 microM. MDL 28,842 (1.0 microM) totally inhibited the generation of cytotoxic T cells when added up to 3 days after the initiation of culture with no apparent cell toxicity. In vivo, MDL 28,842 given by gavage at 5.0, 2.5, or 1.0 mg/kg/day inhibited the increase in popliteal lymph node weight induced by injection of allogeneic spleen cells into the footpad. MDL 28,842 was also evaluated in a model of graft rejection. Skin allografts on animals given MDL 28,842 at 5 mg/kg/day (ip) for the first 6 days following transplantation survived for 12.2 days, compared to 8.7 days for control animals. Cyclosporin A (CSA) given at 5.0 mg/kg/day did not prolong graft survival. The combination of MDL 28,842 and CSA was not any more effective than MDL 28,842 alone. Based on these findings, we suggest that MDL 28,842 is useful in the prevention of allograft rejection.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8330316     DOI: 10.1006/cimm.1993.1165

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  8 in total

1.  An endogenously anti-inflammatory role for methylation in mucosal inflammation identified through metabolite profiling.

Authors:  Douglas J Kominsky; Simon Keely; Christopher F MacManus; Louise E Glover; Melanie Scully; Colm B Collins; Brittelle E Bowers; Eric L Campbell; Sean P Colgan
Journal:  J Immunol       Date:  2011-04-22       Impact factor: 5.422

Review 2.  Transmethylation in immunity and autoimmunity.

Authors:  Brian R Lawson; Theodoros Eleftheriadis; Virginie Tardif; Rosana Gonzalez-Quintial; Roberto Baccala; Dwight H Kono; Argyrios N Theofilopoulos
Journal:  Clin Immunol       Date:  2011-12-24       Impact factor: 3.969

Review 3.  Metabolic shifts in immunity and inflammation.

Authors:  Douglas J Kominsky; Eric L Campbell; Sean P Colgan
Journal:  J Immunol       Date:  2010-04-15       Impact factor: 5.422

4.  Lupus autoimmunity altered by cellular methylation metabolism.

Authors:  Mei-Ling Yang; Alaric J P Gee; Renelle J Gee; Cecilia I Zurita-Lopez; Shilpi Khare; Steven G Clarke; Mark J Mamula
Journal:  Autoimmunity       Date:  2012-11-01       Impact factor: 2.815

5.  Critical role of transmethylation in TLR signaling and systemic lupus erythematosus.

Authors:  Virginie Tardif; Yulia Manenkova; Michael Berger; Kasper Hoebe; Jian-Ping Zuo; Chong Yuan; Dwight H Kono; Argyrios N Theofilopoulos; Brian R Lawson
Journal:  Clin Immunol       Date:  2013-03-05       Impact factor: 3.969

6.  Therapeutic effects of DZ2002, a reversible SAHH inhibitor, on lupus-prone NZB×NZW F1 mice via interference with TLR-mediated APC response.

Authors:  Shi-jun He; Ze-min Lin; Yan-wei Wu; Bing-xin Bai; Xiao-qian Yang; Pei-lan He; Feng-hua Zhu; Wei Tang; Jian-ping Zuo
Journal:  Acta Pharmacol Sin       Date:  2013-12-30       Impact factor: 6.150

Review 7.  Protein Arginine Methyltransferase 5 in T Lymphocyte Biology.

Authors:  Shouvonik Sengupta; Austin Kennemer; Kristin Patrick; Philip Tsichlis; Mireia Guerau-de-Arellano
Journal:  Trends Immunol       Date:  2020-09-02       Impact factor: 19.709

Review 8.  Methionine cycle-dependent regulation of T cells in cancer immunity.

Authors:  Tian Zhao; Julian J Lum
Journal:  Front Oncol       Date:  2022-08-10       Impact factor: 5.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.